Pascal Puglièse
YOU?
Author Swipe
View article: To Switch or not to Switch to Long-acting Injectable Cabotegravir/Rilpivirine in PWH With Past Hepatitis B Virus (HBV) Coinfection: Which HBV Markers to Manage Risk of HBV Reactivation?
To Switch or not to Switch to Long-acting Injectable Cabotegravir/Rilpivirine in PWH With Past Hepatitis B Virus (HBV) Coinfection: Which HBV Markers to Manage Risk of HBV Reactivation? Open
We report the occurrence of low-level hepatitis B virus (HBV) viremia in people with HIV with controlled CD4 counts and isolated core antibody reactivity switched to long-acting injectable cabotegravir/rilpivirine. This series raises quest…
View article: Facilitating the access to HIV testing at lower costs: “To the laboratory without prescription” (ALSO), a pilot intervention to expand HIV testing through medical laboratories in France
Facilitating the access to HIV testing at lower costs: “To the laboratory without prescription” (ALSO), a pilot intervention to expand HIV testing through medical laboratories in France Open
Background A pilot HIV testing programme, Au Labo sans Ordo (ALSO; “to the laboratory without prescription”) was implemented in two French Fast-Track Cities Initiative areas from 07/2019 to 12/2020. ALSO aimed to remove barriers to HIV tes…
View article: Comorbidities, comedications and polypharmacy among people living with HIV and associated challenges with HIV antiretroviral therapy: Findings from people living with HIV in four countries in Western Europe
Comorbidities, comedications and polypharmacy among people living with HIV and associated challenges with HIV antiretroviral therapy: Findings from people living with HIV in four countries in Western Europe Open
Introduction We examined comorbidities, comedications and polypharmacy among people living with HIV (PLHIV) and associated challenges with HIV antiretroviral therapy (ART). Methods A cross-sectional design was used in web-based surveys con…
View article: High syphilis prevalence and incidence in people living with HIV and Preexposure Prophylaxis users: A retrospective review in the French Dat’AIDS cohort
High syphilis prevalence and incidence in people living with HIV and Preexposure Prophylaxis users: A retrospective review in the French Dat’AIDS cohort Open
Background In the past years, we observed a sharp increase of Syphilis, especially among male who have sex with male (MSM), either HIV-infected, or on pre-exposure prophylaxis (PrEP). Our aim was to assess syphilis prevalence and incidence…
View article: To what extent do people living with HIV, people on pre-exposure prophylaxis, doctors and pharmacists endorse 90-day dispensing of antiretroviral therapy in France?
To what extent do people living with HIV, people on pre-exposure prophylaxis, doctors and pharmacists endorse 90-day dispensing of antiretroviral therapy in France? Open
Justification The WHO 95-95-95 targets for 2030 do not imply that people living with HIV (PLHIV) achieve a good quality of life. The current 30-day dispensing interval for antiretroviral (ART) burdens the healthcare system. Lengthening dis…
View article: Incidence of cervical, breast and colorectal cancers between 2010 and 2015 in people living with HIV in France
Incidence of cervical, breast and colorectal cancers between 2010 and 2015 in people living with HIV in France Open
Background We aimed to evaluate the incidence rates between 2010 and 2015 for invasive cervical cancer (ICC), breast cancer (BC), and colorectal cancer (CRC) in people living with HIV (PLWH) in France, and to compare them with those in the…
View article: Spectrum and Incidence Trends of AIDS- and Non–AIDS-Defining Cancers between 2010 and 2015 in the French Dat'AIDS Cohort
Spectrum and Incidence Trends of AIDS- and Non–AIDS-Defining Cancers between 2010 and 2015 in the French Dat'AIDS Cohort Open
Background: Cancer risk is higher in people living with HIV (PLWH) compared with the general population, and cancers related to age are expected to be most prevalent. Methods: We determined the spectrum and incidence rates of AIDS-defining…
View article: Multimorbidity in Elderly Persons According to the Year of Diagnosis of Human Immunodeficiency Virus Infection: A Cross-sectional Dat’AIDS Cohort Study
Multimorbidity in Elderly Persons According to the Year of Diagnosis of Human Immunodeficiency Virus Infection: A Cross-sectional Dat’AIDS Cohort Study Open
Background We assessed prevalence of multimorbidity (MM) according to year of human immunodeficiency virus (HIV) diagnosis in elderly people living with HIV (PLWH). Methods This was a cross-sectional study of MM in PLWH aged ≥70 years from…
View article: Higher rates of HBsAg clearance with tenofovir-containing therapy in HBV/HIV co-infection
Higher rates of HBsAg clearance with tenofovir-containing therapy in HBV/HIV co-infection Open
HBsAg clearance rate was low in HIV-HBV co-infected cART-anti-HBV treated individuals, but was slightly improved on TDF-based regimen.
View article: HIV-related excess mortality and age-related comorbidities in patients with HIV aged ≥60: a relative survival analysis in the French Dat’AIDS cohort
HIV-related excess mortality and age-related comorbidities in patients with HIV aged ≥60: a relative survival analysis in the French Dat’AIDS cohort Open
Objective The objective was to evaluate the association between age-related comorbidities (ARCs) and 5-year HIV-related excess mortality in people living with HIV aged ≥60 years. Design Cohort study using relative survival analysis (Estève…
View article: Antiretroviral exposure and comorbidities in an aging HIV-infected population: The challenge of geriatric patients
Antiretroviral exposure and comorbidities in an aging HIV-infected population: The challenge of geriatric patients Open
As HIV-infected adults on successful antiretroviral therapy (ART) are expected to have close to normal lifespans, they will increasingly develop age-related comorbidities. The objective of this cross-sectional study was to compare in the F…
View article: Derivation and internal validation of a mortality risk index for aged people living with HIV: The Dat'AIDS score
Derivation and internal validation of a mortality risk index for aged people living with HIV: The Dat'AIDS score Open
We propose a multivariable prognostic score for mortality among PLHIV aged 60 or over, who will become the predominant population in future years in western populations. It could be a useful tool for research, for developing preventive and…
View article: Antiretroviral therapy as a risk factor for chronic kidney disease: Results from traditional regression modeling and causal approach in a large observational study
Antiretroviral therapy as a risk factor for chronic kidney disease: Results from traditional regression modeling and causal approach in a large observational study Open
Our results show that combination of TDF and boosted protease inhibitor is associated with a higher CKD risk than TDF and a NNRTI.
View article: Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen
Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen Open
International audience
View article: Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen
Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen Open
In HIV-1-infected patients starting cART, risk of virological rebound was lower with efavirenz or integrase inhibitors than with ritonavir-boosted protease inhibitors. These data, from a very large observational cohort, in addition to the …
View article: Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy - Results from a large french multicenter cohort study
Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy - Results from a large french multicenter cohort study Open
First-line therapy with STRs was associated with a longer time to treatment discontinuation than with non-STRs. However, when ART modification for simplification was not considered as a failure, STRs and non-STRs were similar.
View article: COPD in HIV-Infected Patients: CD4 Cell Count Highly Correlated
COPD in HIV-Infected Patients: CD4 Cell Count Highly Correlated Open
In addition to known risk factors, immune defect through CD4 cell count was independently and strongly correlated with COPD. COPD is largely underdiagnosed and thus unmanaged. However, early management and urgent smoking cessation are esse…
View article: Switch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical Practice
Switch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical Practice Open
Emerging RAL-resistance and discontinuations for adverse events resulted in moderate efficacy rates of ATV and RAL dual therapy in heavily pretreated patients.